CYAD-01, one of Celyad's lead candidates, is an autologous NKG2D-based chimeric antigen receptor T-cell (CAR-T) therapy construct, consisting of a full-length native human NKG2D gene fused with the ...

Some studies suggest that the immunoreceptor NKG2D expression on CD8+ T cells is down-regulated and this reduction may be involved in immune evasion in cancer patients. The present study was designed ...

Autologous genetically engineered NY-ESO-1c259T in HLA-A*02:01, HLA*02:05 and HLA*02:06 positive patients with NY-ESO-1 expressing tumors. This is an ASCO Meeting Abstract from the 2016 ASCO Annual ...

When it comes to engineering proteins, Dr. Roland Strong and his lab in the Division of Basic Sciences, are probably the people you want to talk to. As Dr. Strong described it, “We’ll often take bits ...

Mesenchymal stem cells (MSCs) have long been recognized for their potential in cancer therapy. However, the effectiveness of MSCs in cancer treatment has been hampered by their limited tumor-homing ...

Celyad ($CYAD) has posted data from a Phase I dose-escalation trial of its NKG2D CAR-T cells. None of the participants experienced objective responses at doses Celyad ...

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat ...

LONDON, May 12, 2025 /PRNewswire/ -- Leucid Bio ("Leucid" or "The Company"), a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) ...

In September 2022, LEU011 received the innovative medicine designation, the Innovation Passport, as part of the Innovative Licensing and Access Pathway (ILAP) from the MHRA for the treatment of solid ...